CVR number 30553136
Industry 32.5000 Manufacture of medical and dental instruments and supplies

RADEMACHERS ORTHODONTISKE LABORATORIUM ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  2.2% 2.2% 2.2% 2.2% 2.2%  
Bankruptcy risk  3.0% 4.5% 6.3% 8.1% 7.7%  
Credit score (0-100)  57 45 37 29 32  
Credit rating  BBB BBB BBB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  6,342 6,532 5,704 5,709 6,029  
EBITDA  833 720 79.3 218 258  
EBIT  668 549 -53.9 151 170  
Pre-tax profit (PTP)  639.2 525.2 -61.3 149.8 168.9  
Net earnings  495.9 445.3 -48.6 115.5 130.8  
Pre-tax profit without non-rec. items  639 525 -61.3 150 169  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  292 183 99.8 202 246  
Shareholders equity total  1,496 445 76.4 192 323  
Interest-bearing liabilities  0.0 236 278 385 409  
Balance sheet total (assets)  3,082 1,681 1,089 1,502 1,712  
Net Debt  -2,218 -711 4.3 -297 -0.5  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  6,342 6,532 5,704 5,709 6,029  
Gross profit growth  -8.9% 3.0% -12.7% 0.1% 5.6%  
Employees  11 12 12 12 13  
Employee growth %  -8.3% 9.1% 0.0% 0.0% 8.3%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  3,082 1,681 1,089 1,502 1,712  
Balance sheet change%  30.1% -45.4% -35.2% 37.9% 14.0%  
Added value  833.0 720.3 79.3 283.7 258.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -330 -280 -216 35 -44  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  5.0 5.0 -1.0 1.0 2.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  10.5% 8.4% -0.9% 2.6% 2.8%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  24.5% 23.0% -3.9% 11.6% 10.6%  
ROI %  48.1% 50.2% -10.4% 32.3% 26.0%  
ROE %  36.0% 45.9% -18.6% 86.1% 50.8%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  48.5% 26.5% 7.0% 12.8% 18.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -266.3% -98.7% 5.5% -136.3% -0.2%  
Gearing %  0.0% 52.9% 364.4% 200.4% 126.9%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 20.0% 2.9% 0.2% 0.4%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  1.7 1.1 1.2 1.3 1.4  
Current Ratio  1.7 1.2 1.3 1.4 1.5  
Cash and cash equivalent  2,218.2 946.6 274.1 681.9 409.9  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  1,175.5 226.4 219.1 337.1 441.8  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  76 60 7 24 20  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  76 60 7 18 20  
EBIT / employee  61 46 -4 13 13  
Net earnings / employee  45 37 -4 10 10